UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 318

Sortiert nach

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients

Annals of oncology, 2017-06, Vol.28 (6), p.1325-1332

2017

Volltextzugriff (PDF)

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Annals of oncology, 2012-12, Vol.23 (12), p.3069-3074

2012

Volltextzugriff (PDF)

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

Breast cancer research and treatment, 2012-11, Vol.136 (2), p.487-493

2012

Volltextzugriff (PDF)

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Journal of clinical oncology, 2002-11, Vol.20 (21), p.4292-4302

2002

Volltextzugriff (PDF)

Mechanism of action of anti-HER2 monoclonal antibodies

Annals of oncology, 2001, Vol.12 (suppl-1), p.S35-S41

2001

Volltextzugriff (PDF)

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

British journal of cancer, 2014-10, Vol.111 (8), p.1532-1541

2014

Volltextzugriff (PDF)

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

Clinical & translational oncology, 2018-07, Vol.20 (7), p.815-826

2018

Volltextzugriff (PDF)

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

European journal of cancer (1990), 2022-01, Vol.161, p.26-37

2022

Volltextzugriff (PDF)

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

Annals of oncology, 2012-05, Vol.23 (5), p.1156-1164

2012

Volltextzugriff (PDF)

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

Annals of oncology, 2011-12, Vol.22 (12), p.2646-2653

2011

Volltextzugriff (PDF)

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study

Annals of oncology, 2016-07, Vol.27 (7), p.1249-1256

2016

Volltextzugriff (PDF)

Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells

Cancer research (Chicago, Ill.), 2001-06, Vol.61 (12), p.4744-4749

2001

Volltextzugriff (PDF)

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

Journal of clinical oncology, 2002-01, Vol.20 (1), p.110-124

Albanell, J.

2002

Volltextzugriff (PDF)

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

Annals of oncology, 2012-03, Vol.23 (3), p.625-631

2012

Volltextzugriff (PDF)

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab

Oncoimmunology, 2018-02, Vol.7 (2), p.e1395125-e1395125

2018

Volltextzugriff (PDF)

Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents

Critical reviews in oncology/hematology, 2009-03, Vol.69 (3), p.211-222

2009

Volltextzugriff (PDF)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

British journal of cancer, 2014-03, Vol.110 (5), p.1139-1147

2014

Volltextzugriff (PDF)

MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines

British journal of cancer, 2011-09, Vol.105 (6), p.814-823

2011

Volltextzugriff (PDF)

Potential clinical relevant drug–drug interactions: comparison between different compendia, do we have a validated method?

Annals of oncology, 2015-06, Vol.26 (6), p.1272-1272

2015

Volltextzugriff (PDF)

Unraveling Resistance to Trastuzumab (Herceptin): Insulin-Like Growth Factor-I Receptor, a New Suspect

JNCI : Journal of the National Cancer Institute, 2001-12, Vol.93 (24), p.1830-1832

2001

Volltextzugriff (PDF)

DUSP1 MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer

Oncogene, 2011-02, Vol.30 (6), p.668-678

2011

Volltextzugriff (PDF)

CIP2A confirms its prognostic value in triple-negative breast cancer

Oncogene, 2017-06, Vol.36 (23), p.3357-3358

2017

Volltextzugriff (PDF)

Involvement of miR-99a in resistance to chemotherapy in triple-negative breast cancer

Annals of oncology, 2018-09, Vol.29, p.vi32-vi32

2018

Volltextzugriff (PDF)

Role of miR-449 family on doxorubicin-based chemotherapy response in triple-negative breast cancer

Annals of oncology, 2018-09, Vol.29, p.vi25-vi25

2018

Volltextzugriff (PDF)

Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC)

Annals of oncology, 2017-06, Vol.28, p.iii151-iii151

2017

Volltextzugriff (PDF)

1 – 25 von 318

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(307)
Mit Volltextzugriff
(287)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(136)
Science & Technology
(134)
Life Sciences & Biomedicine
(131)
Oncology
(101)
Female
(84)
Biological And Medical Sciences
(74)
Medical Sciences
(67)
Middle Aged
(58)
Aged
(56)
Male
(48)
Adult
(46)
Pharmacology. Drug Treatments
(37)
Antineoplastic Agents
(35)
Breast Neoplasms - Drug Therapy
(34)
Tumors
(34)
Breast Cancer
(33)
Breast Neoplasms - Pathology
(33)
Chemotherapy
(30)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(29)
Treatment Outcome
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Mechanism of action of anti-HER2 monoclonal antibodies

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study

Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab

Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines

Potential clinical relevant drug–drug interactions: comparison between different compendia, do we have a validated method?

Unraveling Resistance to Trastuzumab (Herceptin): Insulin-Like Growth Factor-I Receptor, a New Suspect

DUSP1 MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer

CIP2A confirms its prognostic value in triple-negative breast cancer

Involvement of miR-99a in resistance to chemotherapy in triple-negative breast cancer

Role of miR-449 family on doxorubicin-based chemotherapy response in triple-negative breast cancer

Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC)

Suchergebnisse filtern